Alpha Tau Medical Ltd ( (DRTS) ) has issued an update.
On February 24, 2025, Alpha Tau Medical Ltd. announced the achievement of Medical Device Single Audit Program (MDSAP) certification for its manufacturing facility in Jerusalem. This certification, which aligns with international regulatory standards, is expected to expedite the company’s global expansion and commercialization efforts for its Alpha DaRT cancer therapy, potentially enhancing its industry positioning and stakeholder value.
More about Alpha Tau Medical Ltd
Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company founded in 2016, focusing on the research, development, and potential commercialization of Alpha DaRT, an innovative alpha-radiation cancer therapy for the treatment of solid tumors. The technology was initially developed by professors from Tel Aviv University.
YTD Price Performance: -13.55%
Average Trading Volume: 94,166
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $187.4M
Find detailed analytics on DRTS stock on TipRanks’ Stock Analysis page.